Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Previous case-control studies have reported inconsistent findings regarding the association between proton pump inhibitor (PPI) use and colorectal cancer (CRC) risk. We investigated these associations using meta-analysis. Methods: We searched MEDLINE (PubMed), EMBASE, and the Cochrane Library in April 2011. Two evaluators independently reviewed and selected articles, based on pre-determined selection criteria. Results: Out of 737 articles meeting our initial criteria, 5 case-control studies, which involved 120,091 participants (9,514cases and 110,577 controls), were included in the final analyses. The overall use of PPI (used vs. never or rarely used) was not significantly associated with the risk of CRC in a fixed-effects model meta-analysis of all 5 case-control studies (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.96 to 1.20; I2 = 3.5%). Also, in sensitivity meta-analysis by cumulative duration of PPI use, there was no association between PPI use of 1 year or longer and the risk of colorectal cancer in a fixed-effects meta-analysis (OR, 1.09; 95% CI, 0.98 to 1.22; I2 = 0%). Conclusion: Although hypergastrinemia could be an important factor in the pathogenesis of some colorectal cancers,our study suggests that this does not lead to significant clinical risk for most PPI users. Further prospective studies or randomized controlled trials related to PPI use and colorectal cancer risk are needed to investigate this association.
Abstract
Background: Previous case-control studies have reported inconsistent findings regarding the association between proton pump inhibitor (PPI) use and colorectal cancer (CRC) risk. We investigated these associations using meta-analysis. Methods: We searched MEDLINE (PubMed), EMBASE, and the Cochrane Library in April 2011. Two evaluators independently reviewed and selected articles, based on pre-determined selection criteria. Results: Out of 737 articles meeting our initial criteria, 5 case-control studies, which involved 120,091 participants (9,514cases and 110,577 controls), were included in the final analyses. The overall use of PPI (used vs. never or rarely used) was not significantly associated with the risk of CRC in a fixed-effects model meta-analysis of all 5 case-control studies (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.96 to 1.20; I2 = 3.5%). Also, in sensitivity meta-analysis by cumulative duration of PPI use, there was no association between PPI use of 1 year or longer and the risk of colorectal cancer in a fixed-effects meta-analysis (OR, 1.09; 95% CI, 0.98 to 1.22; I2 = 0%). Conclusion: Although hypergastrinemia could be an important factor in the pathogenesis of some colorectal cancers,our study suggests that this does not lead to significant clinical risk for most PPI users. Further prospective studies or randomized controlled trials related to PPI use and colorectal cancer risk are needed to investigate this association.
참고문헌 (30)
- Wolfe MM, "Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome", Gastroenterology, 118(2), pp.S9~S31 (2000)
- Van Soest EM, "Persistence and adherence to proton pump inhibitors in daily clinical practice", Aliment Pharmacol Ther, 24, pp.377~385 (2006)
- Bashford JN, "Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database", BMJ, 317, pp.452~456 (1998)
- Smith JP, "Elevated gastrin levels in patients with colon cancer or adenomatous polyps", Dig Dis Sci, 34, pp.171~174 (1989)
- Wong K, "Postprandial hypergastrinaemia in patients with colorectal cancer", Gut, 32, pp.1352~1354 (1991)
- Watson SA, "Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence", Br J Cancer, 87, pp.567~573 (2002)
- La Vecchia C, "A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs", Eur J Cancer Prev, 11, pp.117~123 (2002)
- Watson SA, "Hypergastrinemia promotes adenoma progression in the APC(Min-", +) mouse model of familial adenomatous polyposis, 2001, pp.61, 625~631
- Wu H, "Autocrine gastrins in colon cancer cells Up-regulate cytochrome c oxidase Vb and downregulate efflux of cytochrome c and activation of caspase-3", J Biol Chem, 275, pp.32491~32498 (2000)
- Chubak J, "Colorectal cancer risk in relation to use of acid suppressive medications", Pharmacoepidemiol Drug Saf, 18, pp.540~544 (2009)
- van Soest EM, "Proton pump inhibitors and the risk of colorectal cancer", Am J Gastroenterol, 103, pp.966~973 (2008)
- Robertson DJ, "Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study", Gastroenterology, 133, pp.755~760 (2007)
- Yang YX, "Chronic proton pump inhibitor therapy and the risk of colorectal cancer", Gastroenterology, 133, pp.748~754 (2007)
- [URL]
- Higgins JP, "Quantifying heterogeneity in a meta-analysis", Stat Med, 21, pp.1539~1558 (2002)
- DerSimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7, pp.177~188 (1986)
- Bateman DN, "Mortality study of 18 000 patients treated with omeprazole", Gut, 52, pp.942~946 (2003)
- Singh M, "Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas", Aliment Pharmacol Ther, 26, pp.1051~1061 (2007)
- Hsu WH, "Influence of proton pump inhibitor use in gastrointestinal polyps", Kaohsiung J Med Sci, 26, pp.76~83 (2010)
- Freeman HJ, "Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis", World J Gastroenterol, 14, pp.1318~1320 (2008)
- Freston JW, "Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective", Am J Gastroenterol, 92(4), pp.51S~55S (1997)
- Joshi SN, "Gastrin and colon cancer: a unifying hypothesis", Dig Dis, 14, pp.334~344 (1996)
- Garnett WR, "Considerations for long-term use of protonpump inhibitors", Am J Health Syst Pharm, 55, pp.2268~2279 (1998)
- Nealis TB, "Is there a dark side to long-term proton pump inhibitor therapy?", Am J Ther, 15, pp.536~542 (2008)
- Laine L, "article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors", Aliment Pharmacol Ther, 14, pp.651~668 (2000)
- Siersema PD, "Colorectal neoplasia in veterans is associated with Barrett’s esophagus but not with proton-pump inhibitor or aspirin", NSAID use, 2006, pp.63, 581~586
- Allen JM, "Effect of single dose of omeprazole on the gastrointestinal peptide response to food", Hepatogastroenterology, 31, pp.44~46 (1984)
- Lanzon-Miller S, "Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole", Aliment Pharmacol Ther, 1, pp.239~251 (1987)
- Talley NJ, "Risk for colorectal adenocarcinoma in pernicious anemia: a population-based cohort study", Ann Intern Med, 111, pp.738~742 (1989)
- LeLorier J, "Discrepancies between meta-analyses and subsequent large randomized", N Engl J Med, 337, pp.536~542 (1997)